Position in AZN
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$8,475,824
-$609,712 QoQ
Shares Held
44,699
-24.1% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.48%
of 13F equity value
Holder Rank
#322
of 1,459 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AZN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Catalyst Funds Management Pty Ltd holds $79,371,078 across 9 Drug Manufacturers - General names. AZN ranks #3 (10.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
38,081 | $45,675,497 | |
| 2 | ABBV |
AbbVie Inc.
|
47,019 | $11,831,861 | |
| 3 | AZN |
Astrazeneca PLC
This page
|
44,699 | $8,475,824 | |
| 4 | JNJ |
Johnson & Johnson
|
23,900 | $6,069,883 | |
| 5 | MRK |
Merck & Co., Inc.
|
23,750 | $3,051,875 | |
| 6 | BIIB |
Biogen Inc.
|
11,400 | $2,463,084 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
7,400 | $934,916 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
8,782 | $506,018 |
All Filings in AZN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,475,824 | 44,699 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $9,085,536 | 58,884 | Shares | Sole | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||